glp-1 drugs for weight loss reviews Variety of Help People Without Diabetes Lose Weight: Review Do GLP-1 Supplements Lead to

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status

Bariatric surgery was associated with greater weight loss, but GLP-1 RA therapy was associated with better outcomes

GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS

Reference: Haddad PM et al

New York: Medscape

Body weight control emerged as one of the most important outcomes of GLP-1 RAs therapy in SID, a benefit that is rarely achieved with other antihyperglycaemic treatments